KEKamal M. El-Gamal

Kamal M. El-Gamal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kamal M. El-Gamal has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmacophore‐linked pyrazolo[3,4‐d]pyrimidines as EGFR‐TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies

    by Ahmed A. Gaber, Ahmed M. El‐Morsy, Farag F. Sherbiny, Ashraf H. Bayoumi, Kamal M. El‐Gamal, Khaled El‐Adl, Ahmed A. Al‐Karmalawy, Rogy R. Ezz Eldin, Marwa A. Saleh, Hamada S. Abulkhair

    Targeting the epidermal growth factor receptors (EGFRs) with small inhibitor molecules has been validated as a potential therapeutic strategy in cancer therapy. Pyrazolo[3,4‐d]pyrimidine is a versatile scaffold that has been exploited for developing potential anticancer agents. On the basis of fragment‐based drug discovery, considering the essential pharmacophoric features of potent EGFR tyrosine kinase (TK) inhibitors, herein, we report the design and synthesis of new hybrid molecules of the pyrazolo[3,4‐d]pyrimidine scaffold linked with diverse pharmacophoric fragments with reported anticancer potential. These fragments include hydrazone, indoline‐2‐one, phthalimide, thiourea, oxadiazole, pyrazole, and dihydropyrazole. The synthesized molecules were evaluated for their anticancer activity against the human breast cancer cell line, MCF‐7. The obtained results revealed comparable antitumor activity with that of the reference drugs doxorubicin and toceranib. Docking studies were performed along with EGFR‐TK and ADMET profiling studies. The results of the docking studies showed the ability of the designed compounds to interact with key residues of the EGFR‐TK through a number of covalent and noncovalent interactions. The obtained activity of compound 25 (IC50 = 2.89 µM) suggested that it may serve as a lead for further optimization and drug development.


  • Open Access

    Synthesis, characterization and antimicrobial evaluation of some novel quinoline derivatives bearing different heterocyclic moieties

    by Kamal M. El-Gamal, Mohamed S. Hagrs, Hamada S. Abulkhair

    A series of 3-substituted 6-methoxy-1H-pyrazolo [3,4-b]quinoline derivatives was synthesized by treating 6-methoxy-1H-pyrazolo[3,4-b]quinolin-3-amine (6) with different acid anhydrides including succinic anhydride, maleic anhydride and phthalic anhydride. Also, a series of 3-heteroaryl-2-chloro-6-methoxyquinolines was prepared through 1,3-dipolar cycloaddition of different bi-nucleophiles including hydrazine hydrate, hydroxylamine hydrochloride, thiourea, guanidine hydrochloride, urea and metformin hydrochloride to the chalcone derivative 3-(2-chloro-6-methoxyquinolin-3-yl)-1-(4-methoxyphenyl)prop-2-en-1-one. Structural identifications of all products were reported and the new compounds were screened for their in vitro antimicrobial activity against Streptococcus pneumonia and Bacillus subtilis as examples for Gram-positive bacteria, Pseudomonas aeruginosa and Escherichia coli as examples for Gram-negative bacteria, and Aspergillus fumigatus, Syncephalastrum racemosum, Geotriucum candidum and Candida albicans as representative examples of fungi. The majority of tested compounds showed moderate activities against a wide range of the selected organisms. Among the tested compounds, pyrimidine derivatives 16 and 17 showed the highest antimicrobial activity against gram-positive strains while the highest activity against E. coli as example for Gram-negative strains was observed in the case of 11 and 17. Compounds 14 and 17 were found to be extremely potent against three of the selected fungal strains.